Reverse-Payment Settlements Are Presumptively Anti-Competitive, FTC Argues

Reverse-Payment Settlements Are Presumptively Anti-Competitive, FTC Argues

WASHINGTON, D.C. - The Federal Trade Commission told the U.S. Supreme Court in its opening merits brief on Jan. 22 that reverse-payment settlements of patent litigation between the holder of a drug patent and potential generic manufacturers of the drug are presumptively anti-competitive and unlawful (Federal Trade Commission v. Watson Pharmaceuticals, Inc., et al., No. 12-416, U.S. Sup.).

Find full version on lexis Advance®
Access this news story on lexis.com®